Project Grant R01HL178943
Award Date 8/15/25
Completion Date 5/31/30
Dollars Obligated $730K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to develop a gene editing strategy to correct the CFTR-G542X mutation, the second most common and most prevalent null mutation causing cystic fibrosis (CF). The $129,639 grant, awarded on June 18, 2025, will support research to leverage Type I CRISPR base editing to install a precise single base change and correct the CFTR gene in...
- The Project Grant award of $564,121 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to develop peptide surface-functionalized lipid nanoparticles (PepLNPs) for pulmonary delivery that can reach airway basal cells and use base editing technology to correct specific CFTR gene mutations associated with cystic fibrosis. The goal is to achieve permanent correction of lung disease in cystic fibrosis patients through one-time,...
- This federal Project Grant award of $441,375.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and optimize a dual adeno-associated virus (AAV) system with intein technology to deliver full-length, functional cystic fibrosis transmembrane conductance regulator (CFTR) protein to airway epithelial cells of cystic fibrosis (CF) patients. The goal is to restore CFTR function in CF patients, particularly those...
- This Project Grant award of $629,319.00 from the National Heart Lung and Blood Institute (CFDA #93.837 Cardiovascular Diseases Research) supports research by Emory University to investigate cellular mechanisms for overcoming refractory cystic fibrosis defects. The research aims to identify ribosomal proteins that can partially rescue the synthesis and assembly of cystic fibrosis transmembrane conductance regulator (CFTR) protein variants with premature termination codons, which are associated...
- This Project Grant award, valued at $667,704.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to address hypertrophic cardiomyopathy (HCM), a genetic heart condition affecting 1 in 500 adults. The primary objective is to develop chemically inducible split base editors (SBE) that can precisely and controllably edit the MYBPC3 gene in the heart to correct mutations that cause HCM. The research aims to expand...
- This Project Grant award of $727,575.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to investigate the impact of the SLC26A9 gene on response to CFTR correction therapies for cystic fibrosis (CF) patients. The award will fund research at Children's Hospital Medical Center in Cincinnati, Ohio to evaluate how the SLC26A9 genotype affects lung function and respiratory epithelium physiology in CF patients with varying responses to CFTR...
- This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $750,672 to The Leland Stanford Junior University to conduct research on identifying the cellular protein quality control (PQC) machinery that underlies treatment resistance in cystic fibrosis (CF) patients. The objectives are to: 1) comprehensively identify genes that govern the stability of the most common CF-causing variant (F508del)...
- The federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to understand the mechanisms linking the cystic fibrosis transmembrane conductance regulator (CFTR) gene to dysregulated barrier function, insulin receptor function, and glucose transport in the lungs of cystic fibrosis (CF) patients. The $730,494 award to Emory University, with a sub-award to Vanderbilt University Medical Center, aims to investigate...
- The federal Project Grant award of $507,000.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop an automated system that integrates micro-electromechanical sensors, automation, and machine vision to simultaneously measure electrophysiological properties and contractile forces in single human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). This innovative system is expected to significantly reduce measurement time...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...